Patients with hepatocellular carcinoma undergoing living donor liver transplantation have worse recurrence-free survival compared to deceased donor liver transplants.
Dr Chao and colleagues from the USA assessed whether a short waitlist time or fast-tracking may include more aggressive tumors that would have been selected out by longer waitlist time.
The team conducted a study to evaluate the impact of waitlist time on hepatocellular carcinoma recurrence.
The study cohort included 100 patients meeting T2 criteria by imaging.
The research team reported that 90 patients underwent deceased donor liver transplantation and 10 patients received living donor liver transplantation.
The research team found that 5-year recurrence-free probability was 90% for the entire cohort.
|The 5-year recurrence-free probability was 92% for a waitlist time of 3 months or less|
|American Journal of Transplantation|
The 5-year recurrence-free probability was 92%, 91% and 87%, respectively, for a waitlist time of 3 months or less, 3 to 6 months and more than 6 months.
The team found that waitlist time was not a significant predictor of hepatocellular carcinoma recurrence.
Tumor under-staging was observed in 21% of patients with waitlist time 3 months or less and 23% for waitlist time more than 3 months.
Dr Chao's team concluded, "Our results failed to show an association between waitlist time and outcome after deceased donor liver transplantation or living donor liver transplantation for hepatocellular carcinoma ."
"This study provides evidence disputing a significant role of waitlist time in the selection against hepatocellular carcinoma with unfavorable tumor biology."